vimarsana.com
Home
Live Updates
Johnson & Johnson submits supplemental Biologics License Application to U.S. FDA seeking approval of TREMFYA® (guselkumab) for the treatment of adults with moderately to severely active ulcerative colitis : comparemela.com
Johnson & Johnson submits supplemental Biologics License Application to U.S. FDA seeking approval of TREMFYA® (guselkumab) for the treatment of adults with moderately to severely active ulcerative colitis
/PRNewswire/ -- Johnson & Johnson today announced the submission of a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug...
Related Keywords
Japan ,
Canada ,
Spring House ,
British Columbia ,
Canadian ,
David Lee ,
Scandj Rheumatol ,
Prnewswire Johnson ,
Craig Stoltz ,
Exchange Commission ,
Devices Agency ,
Drug Administration ,
Johnson ,
Canadian Agency For Drugs Technologies In Health ,
European Commission ,
None Of Janssen Research Development ,
Japan Pharmaceuticals ,
National Institutes Of Health ,
Janssen Biotech Inc ,
Crohn Colitis Foundation ,
Janssen Research Development ,
Biologics License Application ,
Global Therapeutic Area Head ,
Disease Week ,
Prescribing Information ,
Medication Guidefor ,
Private Securities Litigation Reform Act ,
Janssen Research ,
Janssen Biotech ,
Annual Report ,
Note Regarding Forward Looking ,
Quarterly Reports ,
Innovative Medicine ,
Accessed February ,
Digestive Disease Week ,
Invest Dermatol ,
Canadian Agency ,
Medical Devices ,
Tremfya Report ,
Johnson Amp ,
comparemela.com © 2020. All Rights Reserved.